Paclitaxel albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer
Status Suspended
Process STA pre-2018
Referral date 01 August 2015

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Associate Director: Helen Knight
Communications manager: TBC
Project manager:

Kate Moore

Technical Advisor: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
25 September 2015 This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the manufacturer of paclitaxel has informed us that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal and we will provide further updates when they are available.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance